Shree Ganesh Remedies Ltd

The provided transcript from the Shree Ganesh Remedies Limited Q2 & H1 FY26 Earnings Conference Call does not mention any current or future plans for fundraising through debt or equity. Key points related to finances and expansion include: - The company is focused on consolidation and capability building in FY’26. - Capital investments are ongoing to expand capacity and capabilities. - There is no specific reference to issuing new debt or equity. - Expansion projects like Block 7 and 8 and a new plant at Dahej are underway, funded through existing means. - Management did not indicate any plans for external fundraising during the call. Hence, based on the call transcript, there is no guidance or information shared about new fundraising through debt or equity currently or planned in near future.

- Shree Ganesh Remedies Limited is undertaking expansion and capacity-building initiatives. - Recently commissioned Block 8 in Unit 1, with capacity utilization expected to reach 50% to 60% by year-end. - Block 7 is under construction with commercial production planned for the second half of FY’27. - Expansion is taking place on newly acquired adjoining property (former Jaiswal Pharma Chem). - Dahej plant expansion planned with a timeline of about two years from now, focusing on bulkier specialty commodity or high-volume products developed collaboratively with customers. - New pilot facility commissioning is in final stages and expected operational by Q4 FY’26. - Capital investments aim to capture opportunities in complex, value-added chemistries and differentiated manufacturing solutions. - FY’26 is focused on consolidation and capability building to lay the foundation for sustainable scaled growth.

- FY’26 is considered a year of consolidation and capability building; sales expected to be similar to FY’25. - Commercial volumes for new molecules are under evaluation; clarity on FY’27 growth is currently uncertain. - Anticipated initial volume pickup for new products expected by Q2 FY’27. - Post FY’27, growth is linked to commercial scale-up of innovator molecules and specialty chemicals. - New agrochemical product expected to reach peak sales by 2029-2030. - Expansion projects (Block 7 and Dahej plant) targeted to enable future growth with higher volume products. - Transition from generic to innovator molecules over 3-4 years expected to contribute significantly to revenue. - Margin guidance of around 26% to 30% with sustainable profitability from existing and new products. - Specialty chemical initiatives in Japan and Europe present growth opportunities in new sectors (e.g., semiconductors).

- FY’26 is a consolidation year focused on capability building, with no major growth guidance for this year. - Margins expected to stay healthy around 26%-30% despite market softness. - Revenue expected to remain similar to last year (no significant increase anticipated for FY’26). - Growth visibility for FY’27 and beyond is currently uncertain due to pending commercial approvals and customer order clarity. - Pilot-scale approvals underway for innovative and specialty molecules, with commercial volume pickups anticipated from Q2 FY’27. - New products and capacity expansions (Blocks 7 & 8) to contribute over medium to long term. - Long-term growth drivers include specialty chemicals, agrochemicals, and innovator pharmaceutical molecules maturing into larger revenue streams in 3-4 years. - Management expects growth to be lumpier and non-linear in short term but healthy and sustainable over medium to long term, with potential for meaningful value creation in future years.

- The company is in a consolidation phase for FY’26 with sales expected to be similar to last year. - New product trials and approvals are ongoing, with initial volumes from new projects anticipated by Q2 FY’27. - Supply for some innovator molecules will start before generic launch, with commercial scaling expected in 3-4 years. - Agrochemical projects have received client approvals; bulk purchasing expected to start in 2027 with peak sales around 2029-2030. - Specialty chemicals projects for the Japanese market are advancing with expected client approval by mid-2026. - Block 7 expansion is underway with commercial production planned for H2 FY’27. - The company has a strong order pipeline, with ongoing customer evaluations and sample approvals, though specific order book numbers were not disclosed due to confidentiality.